GGrantIndex
← Search

Cancer Research Training and Education Coordination

$155,034P30FY2023CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

Program Director/Principal Investigator (Last, First, Middle): Chu, Edward CANCER RESEARCH TRAINING AND EDUCATION COORDINATION - PROJECT SUMMARY/ABSTRACT To fulfill the MECC’s mission to train a diverse biomedical workforce, CRTEC is committed to education, training, and career development activities that promote a better understanding of the origins of cancer and the effective detection, prevention, and treatment of these diseases. CRTEC fosters education and training across the entire educational spectrum, including high school students, undergraduates, medical and graduate students, postgraduate trainees, junior faculty, community physicians, and other healthcare providers. CRTEC activities are organized into three Specific Aims that provide career enhancement opportunities across the biomedical training pipeline and develop the next generation of cancer researchers. Aim 1 will coordinate MECC and institutional programming to educate and inspire high school students, undergraduates, predoctoral and postdoctoral trainees and junior faculty to pursue careers in cancer research. Key activities include implementing and expanding MECC high school and undergraduate pipeline programs, which focus on historically underrepresented populations, expanding MECC’s extramurally funded training grant portfolio and ensuring that the training pipeline is diverse and inclusive. Aim 2 will support career and professional development activities across the educational continuum. Key activities include enhancing the mentorship program for junior faculty through an iterative process of review and refinement, providing mentor (faculty) and mentee (postdoctoral fellows and graduate students) training, offering career exploration workshops with a focus on alternative careers in cancer research, and providing training and opportunities for trainees in the communication of cancer research innovations to audiences in the Bronx catchment area. Aim 3 will track and assess the impact of MECC’s cancer training and education activities. Key activities will include providing travel awards for trainees to present at cancer meetings or workshops for skills development, incorporating trainees into the annual MECC retreat and maintaining a trainee database to follow career progression and outcomes. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page

View original record on NIH RePORTER →